Last reviewed · How we verify
Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation
Approved treatments
- Yervoy · Bristol-Myers Squibb
Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells. - Yervoy · Bristol-Myers Squibb
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation patent landscape — cliff calendar, originator estates, attackable patents
- Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation treatment landscape brief
- Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation treatment updates RSS
Frequently asked questions about Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation
What drugs treat Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation?
Tracked treatments include Yervoy.
What is the treatment for Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation?
Standard treatment for Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation includes Yervoy. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation patent cliff · Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation CI report
- Treatment: Yervoy · Bristol-Myers Squibb
- Treatment: Yervoy · Bristol-Myers Squibb
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing